



# Chemotherapy

accuracy and diversity of modern treatment methods does  
effective set of treatment for each patient individual  
toxic, has no contraindications to repeated  
compared with standard therapy



## NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER 1-DAY VIRTUAL TRAINING COURSE

29<sup>th</sup> October 2021 | Virtual Conference Centre  
Provided by EBCSS Events 2021

### PROGRAMME



**EXACT  
SCIENCES**





Edinburgh & Lothians  
Health Foundation



## Neoadjuvant Chemotherapy Teaching Day Friday, 29<sup>th</sup> October 2021

07.40-07.50 MAIN VIRTUAL AUDITORIUM: Welcome address from **Prof Mike Dixon**

MAIN VIRTUAL AUDITORIUM			
Speaker	Talk Title	UK Time	China Time
<b>MORNING SESSION</b>			
Session Chair: Dr Arran Turnbull			
<b>Neoadjuvant chemotherapy and subtypes of breast cancer</b>			
Prof Mike Dixon	Why use neoadjuvant therapy?	07.50-08.10	15.50-16.10
Prof David Cameron	Early neoadjuvant studies and neoadjuvant chemotherapy for ER+ breast cancer	08.10-8.40	16.10-16.40
Dr Olga Oikonomidou	Neoadjuvant chemotherapy for HER2+ breast cancer	08.40-09.00	16.40-17.00
Prof Lisa Carey	Neoadjuvant chemotherapy for triple negative breast cancer	09.05-09.25	17.05-17.25
Prof Mike Dixon	Neoadjuvant chemotherapy versus endocrine therapy for ER+ patients	09.30-10.00	17.30-18.00
Morning Break (30 minutes): visit virtual exhibitor hall, visit network hall			
<b>Sponsored satellite symposia (10.00-10.45) – Roche Products Ltd</b> Dr Ben Langley, Clinical Research Fellow, Western General Hospital <i>One year of experience of adjuvant Kadcyla across The Southeast Scotland Cancer Network (SCAN)</i>			
			
<b>MID-MORNING SESSION</b>			
Session Chair: Prof Mike Dixon			
<b>Neoadjuvant Chemotherapy and Predictors of Response</b>			
Dr Arran Turnbull	Tumour subtypes and classification	10.45-11.05	18.45-19.05

	including genomic predictors		
Dr Peter Hall	Which patients should get neoadjuvant chemotherapy & use of genomic predictors	11.10-11.30	19.10-19.30
Prof Fraser Symmans	Residual cancer burden and prognosis	11.35-11.55	19.35-19.55
Morning Session Speakers	Morning Session – Interactive Q&A	12.00-12.30	20.00-20.30
Lunch Break (90 minutes): visit virtual exhibitor hall, visit network hall			
<b>Sponsored satellite symposia (12.30-13.15) – Exact Sciences</b> Professor Christos Markopoulos <i>Clinical utility of multigene assays in early breast cancer: Predictive tests</i>			
<b>AFTERNOON SESSION</b> Session Chair: Prof Mike Dixon			
<b>Neoadjuvant Chemotherapy Studies: Lessons and End Points</b>			
Prof Lisa Carey	Is pathological complete response a valid endpoint in neoadjuvant studies?	14.00-14.20	22.00-22.20
Prof Laura Esserman	Use of the neoadjuvant model to identify new agents: lessons from I SPY	14.25-14.55	22.25-22.55
<b>Neoadjuvant Immunotherapy</b>			
Prof Beth Mittendorf	Neoadjuvant immunotherapies in breast cancer	15.00–15.20	23.00-23.20
<b>Managing the Nodes and Axilla</b>			
Mr Jay Kulkarni	Principles of disease marking in neoadjuvant chemotherapy	15.25–15.45	23.25-23.45
Afternoon Session Speakers	Afternoon Session – Interactive Q&A	15.50-16.10	23.50-00.10
Afternoon Break (30 minutes): Explore virtual exhibitor hall, visit the network hall			
<b>LATE AFTERNOON SESSION</b>			

Session Chair: Prof Mike Dixon			
<b>Interactive Clinical Case Discussion (MDM)</b>			
Mr Jay Kulkarni, Dr Olga Oikonomidou, Dr Frances Yuille, Prof Mike Dixon	MDM discussion of example clinical cases & questions from the audience	16.40-17.20	00.40-01.20
<b>Surgery After Chemotherapy</b>			
Prof Mike Dixon	Safety of breast conserving surgery after neoadjuvant therapy: management of the axilla	17.25-17.45	02.25-01.45

17.50-18.00 MAIN VIRTUAL AUDITORIUM: Closing Remarks from **Prof Mike Dixon**